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ABSTRACT: Botulinum neurotoxin (BoNT) A and B are
used to treat neuropathic disorders; if retargeted, these
agents could be used to treat medical conditions that
involve secretion from nonneuronal cells. Here, we report
novel strategies for successfully retargeting BoNTs, and
also tetanus neurotoxin (TeNT), to primary human blood
monocyte-derived macrophages where BoNT/B inhibited
the release of tumor necrosis factor-α, a cytokine that plays
a key role in inflammation. Furthermore, mice treated with
retargeted BoNT/B exhibited a significant reduction in
macrophage (MΦ) recruitment, indicating that these
toxins can be used to treat chronic inflammation.
T
he clostridial neurotoxins (CNTs), which include seven
BoNT serotypes (A−G) and tetanus neurotoxin (TeNT),
have been integral for studying neuroexocytosis.
1 Intoxication
by BoNTs causes flaccid paralysis, whereas TeNT causes rigid
paralysis. Currently, most, if not all, therapeutic applications of
the BoNTs involve the inhibition of the release of neuro-
transmitters from neurons.
2 The targets for these toxins are
neuronal SNARE proteins. SNAREs, which include syntaxin
and SNAP-25 on the target membrane and synaptobrevin on
vesicles, form the core of a conserved membrane fusion
machine that mediates neuronal exocytosis.
1,3
However, it is well established that SNARE proteins are
ubiquitously expressed and are important for secretion in many
other cell types, which include immune cells, including
eosinophils, neutrophils, MΦs, and mast cells.
4,5 Inhibition of
secretion from these cells, using CNTs, could revolutionize
treatment options for allergies (mast cells) and chronic
inflammation (MΦs). However, the full therapeutic potential
of these toxins has not been fulfilled because of the lack of toxin
receptors on nonneuronal cells.
To target the toxins to nonneuronal cells, it was important to
first investigate whether they were functionally active in the
absence of their native receptors. HEK-293 cells were used as a
model system to study alternative entry methods because of
their lack of native toxin receptors. However, because most of
the CNTs enter neurons via recycling synaptic vesicles,
6,7 it was
important to retarget the toxins to an alternative vesicular
compartment that is more commonly found in nonneuronal
cell types.
Our strategy for redirecting the CNTs was to utilize the low-
density lipoprotein receptor (LDLR), which is recycled through
endosomes in virtually all cell types.
8 We transfected HEK-293
cells with an avidin-LDLR (AvLDLR) construct (Figure S1a of
the Supporting Information) and then incubated the cells with
biotinylated CNTs (Figure S1b of the Supporting Informa-
tion). HEK-293 cells that were transfected with AvLDLR
exhibited robust entry of several CNTs, as evidenced by
significant cleavage of exogenously introduced SNAP-25 by
biotinylated BoNT/A (biotin-BoNT/A) and biotin-BoNT/E
(Figure S2a of the Supporting Information), and cleavage of
transfected synaptobrevin II (syb II) by biotin-BoNT/B, biotin-
BoNT/F, and biotin-TeNT (Figure S2b of the Supporting
Information). Collectively, these results clearly demonstrate
that the CNTs are active when retargeted to an alternative
organelle lacking native toxin receptors, as suggested by a
previous study.
9
The fact that many primary cells are resistant to genetic
modification
10 makes it difficult to introduce the CNTs via
chimeric receptors. To overcome this obstacle, we used avidin
to tether biotin-toxin to biotin-transferrin (Tr) or to a biotin-
antibody directed against the extracellular domain of the LDLR
to target recycling endosomes (Figure 3a of the Supporting
Information). Indeed, when biotin-BoNT/A or biotin-BoNT/E
was linked to the antibody or Tr through avidin, there was
significant cleavage of SNAP-25 (Figure S3b,c of the
Supporting Information). In addition, when biotin-BoNT/B,
biotin-BoNT/F, or biotin-TeNT was attached to Tr, the toxins
were able to enter cells and cleave their substrate, syb II (Figure
S3d of the Supporting Information).
The next goal was to determine whether these toxins could
be retargeted to MΦs, which are phagocytes that participate in
various defense mechanisms in immune responses. They also
play a maladaptive role in diseases, including sepsis,
atherosclerosis, cancer, and chronic inflammatory disorders,
including rheumatoid arthritis and Crohn’s disease.
5
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line, and cleave SNAREs, we modified the antibody-mediated
delivery method and targeted the toxin to the Fc and
complement receptor-mediated endocytosis pathway. Cellu-
brevin (ceb) levels in cells incubated with BoNT/B alone and
BoNT/B with an anti-BoNT/A antibody (αA) were unaffected.
With BoNT/B and αB (anti-BoNT/B), the toxin was able to
enter cells and cleave ceb (Figure 1a). None of these treatments
significantly affected cell viability (Figure 1b).
In addition to their ability to phagocytose and degrade
microbes, MΦs also release a variety of cytokines that regulate
inflammation and the recruitment of other immune cells. To
determine the effect of SNARE cleavage by retargeted BoNT/
B, we measured the release of cytokines and other factors from
human BMDMs. Cells treated with BoNT/B, in conjunction
with αB, exhibited an ∼50% decrease in interferon-γ and
lipopolysaccharide (IFNγ/LPS)-induced TNFα release, with-
out significantly affecting cell viability (Figure 2a and Figure
S4a of the Supporting Information). We did not observe a
reduction in the release of other cytokines and factors from
these cells (Figure S5 of the Supporting Information).
The secretion of TNFα, a potent pro-inflammatory cytokine
secreted primarily by MΦs and monocytes,
11 is thought to play
a critical role in many diseases.
5,11−13 A dose−response study
revealed that the IC50 of retargeted BoNT/B on TNFα release
was ∼6 nM (Figure 2b). This effect was specific; the release of
matrix metalloproteinase-9 (MMP-9), monitored as a control,
was not reduced by the retargeted toxin, demonstrating that
this enzyme is secreted through a distinct, BoNT/B-insensitive
pathway (Figure S4b of the Supporting Information).
Furthermore, the decrease in TNFα release was not associated
with cytotoxicity (Figure S4c of the Supporting Information).
We note that the increases in metabolic activity at higher doses
of retargeted toxin might potentially explain the concomitant
increase in MMP-9 release over this concentration range. The
donor pool mainly consisted of two groups: clinically diagnosed
allergic asthmatics and allergic patients without asthma. Human
BMDMs from both groups exhibited significant decreases in
TNFα release (Figure 2c,d).
The antibody-mediated delivery method illustrates the
effectiveness in retargeting BoNT/B to human BMDMs;
however, use of the intact toxin can potentially result in the
intoxication of neuronal cells. Therefore, further experiments
were performed utilizing a truncated toxin, BoNT/BΔHC,
which lacks the HC domain that mediates interactions with
native receptors on neurons.
1
To produce BoNT/BΔHC, we took advantage of a
hypersensitive chymotrypsin site that lies between the trans-
location (HN) and HC domain of the protein (Figure S6a of
the Supporting Information).
14 Toxin that was treated with
chymotrypsin resulted in an ∼113 kDa fragment, which could
be reduced by β-mercaptoethanol (BME) into two fragments
corresponding to the HN domain and L chain (Figure S6b,c of
the Supporting Information). To confirm the removal of the
neurospecific binding domain, we tested whether BoNT/
BΔHC could enter and intoxicate hippocampal neurons. As
expected, BoNT/BΔHC had no detectable activity as
demonstrated by the lack of syb II cleavage (Figure S6d of
the Supporting Information). Thus, BoNT/BΔHC, preincu-
bated with the antibody, is not targeted to neurons.
Next, primary human BMDMs treated with BoNT/BΔHC
and αB led to a ∼25% decrease in TNFα release (Figure 3a),
indicating that the HC domain is dispensable for targeted entry
into human BMDMs. Finally, when BoNT/BΔHC and αB
were administrated in mice with thioglycollate-induced
inflammation, FACS (fluorescence-activated cell sorting)
analysis revealed an ∼35% decrease in the extent of MΦ
Figure 1. BoNT/B incubated with a serotype-specific antibody enters
RAW 264.7 cells to cleave ceb. (a) BoNT/B (50 nM) and αB
(combined at a 1:1 molar ratio) were combined and incubated with
RAW 264.7 cells for 48 h, resulting in cleavage of 68% of ceb. ceb
levels were unaffected in cells incubated with BoNT/B alone or
BoNT/B incubated with αA. (b) MTS assay indicating no significant
decrease in metabolic activity in response to toxin treatment vs the
control. Error bars represent the standard error of the mean (SEM) (n
= 3).
Figure 2. Retargeted BoNT/B reduces the secretion of TNFα from
primary human BMDMs. (a) Release of TNFα from human BMDMs
monitored by ELISA. When BoNT/B (6 nM) and αB (combined at a
1:1 molar ratio) were incubated with BMDMs for 48 h, the release of
TNFα was reduced by 45%. The trial with antibody and BoNT/B
alone was not significantly different from the control. Error bars
represent SEM (n = 7; p ≤ 0.01). (b) Dose response of retargeted
BoNT/B on the release of TNFα from human BMDMs (fitted line
colored gray). The concentrations indicated are for BoNT/B, which
was preincubated with αB. Error bars represent SEM (n ≥ 3; R2 =
0.65; IC50 = 6.1 nM). (c and d) The release of TNFα from human
BMDMs from allergic asthmatic patients (c) was reduced by 50%,
while BMDMs from allergic patients with no diagnosis of asthma (d)
exhibited a 39% reduction when incubated with 6 nM retargeted
BoNT/B. Error bars represent SEM (n ≥ 5; p ≤ 0.01).
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state of inflammation (Figure 3b,c). These data further confirm
that BoNT/BΔHC is effective at suppressing selective
inflammatory responses both in vitro and in vivo.
To further investigate the effects of BoNT/B on MΦ
recruitment, we investigated whether retargeted toxins affected
integrin trafficking in RAW 264.7 cells. Adhesion through β1
integrins and activation of CD11b are thought to be critical for
differentiation of monocytes to MΦs.
15,16 We observed no
significant differences in adhesion between treated and
untreated cells (Figure S7a of the Supporting Information) or
in CD11b surface expression (Figure S7b of the Supporting
Information). Thus, we believe the reduction in the level of
intraperitoneal MΦs is largely due to the reduced extent of
recruitment of monocytes and leukocytes because of decreased
levels of TNFα.
17
The CNTs are powerful therapeutic agents that reduce the
symptoms of many profound diseases, including cervical
dystonia and migraine headaches.
18 The findings reported
here demonstrate that these toxins can be engineered to target
cells other than neurons.
19 In particular, targeting the CNTs to
human MΦs can help alleviate symptoms in many diseases such
as rheumatoid arthritis, Crohn’s disease, psoriasis, and
refractory asthma.
13 Blocking the effects of TNFα has also
been shown to inhibit tumor vascularization
12 and the
progression of atherosclerosis.
11 With the added benefit of
the prolonged effects of BoNT/B,
18 this strategy introduces a
powerful new class of therapeutics.
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Figure 3. Retargeting of BoNT/BΔHC to MΦs. Injection into mice
reduces the extent of MΦ recruitment in vivo. (a) The release of
TNFα was assessed after treatment with BoNT/BΔHC (1 nM) and
αB for 48 h and reduced by 23% vs the control. Error bars represent
SEM (n = 3; p ≤ 0.05). (b) FACS analysis of intraperitoneal cells,
isolated from mice treated with the indicated agents, exhibited a
significant decrease in the CD-115-positive MΦ population (red line)
in the presence of BoNT/BΔHC and αB. Cells incubated with a
control antibody are represented by the dark gray area. (c) Mice
treated with a mixture of BoNT/BΔHC (25 ng) and αB (42 ng)
exhibited an ∼35% decrease in the extent of MΦ recruitment 4 h post-
treatment, while neither protein alone exhibited a decrease vs the
control. Error bars represent SEM (n ≥ 8; p ≤ 0.05).
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